09:00 AM EDT, 03/18/2024 (MT Newswires) -- Health care stocks were edging higher premarket Monday as the iShares Biotechnology ETF (IBB) was unchanged and the Health Care Select Sector SPDR Fund (XLV) was up 0.3% recently.

Fennec Pharmaceuticals ( FENC ) was advancing by more than 6% after announcing an exclusive licensing agreement with Norgine to commercialize Pedmarqsi, which is intended for the prevention of hearing loss induced by cisplatin chemotherapy in patients one month to less than 18 years old with localized, non-metastatic solid tumors.